Latest Articles

Publication Date
GSK posts encouraging data for endometrial and ovarian cancer drug - London South East

GSK posts encouraging data for endometrial and ovarian cancer drug London South East

Published: April 13, 2026, 6 a.m.
Plasma proteomic signature of the human menstrual cycle.

The menstrual cycle is one of the most fundamental biological rhythms in human physiology, yet its systemic molecular changes remain poorly understood. Here we show that the menstrual cycle is …

Published: April 13, 2026, midnight
The Effect of Curcumin on Angiogenic and Proliferative Factors inHuman Endometriotic Cells.

Endometriosis is a benign gynaecological disorder characterised by the presence of endometrial-like tissue outside the uterus. Proliferation of endometrial tissue and neoangiogenesis are essential factors in the development of endometriosis. …

Published: April 13, 2026, midnight
Unravelling Multilayered RNA Modification Networks in Female Reproduction and Obstetric/Gynaecologic Disorders.

Background/Objective: RNA modifications, including N6-methyladenosine (m6A), 5-methylcytosine (m5C), 7-methylguanosine (m7G), N1-methyladenosine (m1A), pseudouridine (Ψ), N4-acetylcytidine (ac4C), 5-methoxycarbonylmethyl-2-thiouridine (mcm5s2U) and adenosine-to-inosine (A-to-I) editing, constitute a critical layer of post-transcriptional regulation that …

Published: April 13, 2026, midnight
SYS6043 Shows Initial Antitumor Activity in Pretreated Ovarian, Endometrial, and Cervical Cancer - OncLive

SYS6043 Shows Initial Antitumor Activity in Pretreated Ovarian, Endometrial, and Cervical Cancer OncLive

Published: April 12, 2026, 9:35 p.m.
Data From the CARE Trial in Recurrent/Advanced Endometrial Cancer - OncLive

Data From the CARE Trial in Recurrent/Advanced Endometrial Cancer OncLive

Published: April 12, 2026, 9:28 p.m.
Dr Yang on the Activity of Cadonilimab/Chemo in Recurrent/Advanced Endometrial Carcinoma - OncLive

Dr Yang on the Activity of Cadonilimab/Chemo in Recurrent/Advanced Endometrial Carcinoma OncLive

Published: April 12, 2026, 9:10 p.m.
Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer - OncLive

Efficacy of Pamirtecan in HER2-Expressing Endometrial Cancer OncLive

Published: April 12, 2026, 9:01 p.m.
Dr Pothuri on Preliminary Data With Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer - OncLive

Dr Pothuri on Preliminary Data With Trastuzumab Pamirtecan in HER2-Expressing Endometrial Cancer OncLive

Published: April 12, 2026, 9 p.m.
Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug - MedPage Today

Encouraging Activity in Poor-Risk Endometrial Cancer With HER2-Targeted Novel Drug MedPage Today

Published: April 12, 2026, 8:01 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!